ALERT

Serious adverse effects resulting from the treatment with thalidomide prompted modern drug legislation more than 40 years ago. Post-marketing spontaneous reporting systems for suspected adverse drug reactions (ADRs) have been a cornerstone to detect safety signals in pharmacovigilance. It has become evident that adverse effects of drugs may be detected too late, when millions of persons have already been exposed.

In this project, an alternative approach for the detection of ADR signals will be developed. Rather than relying on the physician's capability and willingness to recognize and report suspected ADRs, the system will systematically calculate the occurrence of disease (potentially ADRs) during specific drug use based on data available in electronic patient records. In this project, electronic health records (EHRs) of over 30 million patients from several European countries will be available. In an environment where rapid signal detection is feasible, rapid signal assessment is equally important. To rapidly assess signals, a number of resources will be used to substantiate the signals: causal reasoning based on information in the EHRs, semantic mining of the biomedical literature, and computational analysis of biological and chemical information (drugs, targets, anti-targets, SNPs, pathways, etc.).

The overall objective of this project is the design, development and validation of a computerized system that exploits data from electronic healthcare records and biomedical databases for the early detection of adverse drug reactions. The ALERT system will generate signals using data and text mining, epidemiological and other computational techniques, and subsequently substantiate these signals in the light of current knowledge of biological mechanisms and in silico prediction capabilities. The system should be able to detect signals better and faster than spontaneous reporting systems and should allow for identification of subpopulations at higher risk for ADRs.

For further information, please visit:

Project co-ordinator:
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Partners:

  • SOCIETA SERVIZI TELEMATICI SRL
  • UNIVERSIDADE DE AVEIRO
  • THE UNIVERSITY OF NOTTINGHAM
  • PHARMO COOPERATIE UA
  • AARHUS UNIVERSITETSHOSPITAL, AARHUS SYGEHUS
  • UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
  • UNIVERSITAT POMPEU FABRA
  • IRCCS CENTRO NEUROLESI BONINO PULEJO
  • FUNDACIO IMIM
  • LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
  • ASTRAZENECA AB
  • UNIVERSITE VICTOR SEGALEN BORDEAUX II
  • AGENZIA REGIONALE DI SANITA
  • UNIVERSITA DEGLI STUDI DI MILANO - BICOCCA

Timetable: from 02/2008 – to 07/2011

Total cost: € 5.880.600

EC funding: € 4.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

Contact Tracing Apps Unlikely to Contain…

Contract tracing apps used to reduce the spread of COVID-19 are unlikely to be effective without proper uptake and support from concurrent control measures, finds a new study by UCL...

Philips Launches New Innovations to Help…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today presented new approaches to health and healthcare, and the shift to health-at-home, at its virtual consumer health...

Internet Searches for Anxiety Attacks Ta…

Many health experts are concerned that the COVID-19 pandemic could be having widespread effects on people's mental health, but assessing these concerns is difficult without data. "Traditional public health surveillance lacks...

Orion Health Secures Place on Emerging T…

Remote Patient Monitoring solution included on Crown Commercial Services Spark: Technology Innovation Marketplace. Healthcare organisations now have a simple route to procure personalised monitoring for people living with chronic conditions to...

Scientists Develop Low-Cost Chip to Dete…

Robust and widespread antibody testing has emerged as a key strategy in the fight against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. However current testing methods are too inaccurate...

Newly Merged CCG Expands Tech Support to…

Norfolk and Waveney Clinical Commissioning Group to support prescribers to improve the quality and safety of prescribing through deploying prescribing decision technology FDB OptimiseRx. A newly merged clinical commissioning group...

Anonymized Cell Phone Location Data can …

In March 2020, federal officials declared the COVID-19 outbreak a national emergency. Around the same time, most states implemented stay-at-home advisories - to different degrees and at different times. Publicly...

Designed Antiviral Proteins Inhibit SARS…

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. The findings are reported today in Science. In the experiments, the lead...

Telehealth Scales Up During the Pandemic…

Hailed for its ability to erase distance between health care providers in cities and patients in rural areas, telehealth has ironically enabled medical care to continue in a time when...

Fitbit Receives Regulatory Clearance in …

Fitbit (NYSE:FIT) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as Conformité Européenne (CE) marking in the European Union, for its electrocardiogram (ECG) app...

Don't Fall for the 'Next Best Action' Tr…

15 September, 2020. London, UK. OKRA has announced a new, free webinar called 'Why Next Best Action is not enough', a panel will discuss the urgent need to move beyond the...

Cerner Chosen to Support Population Heal…

Cerner Corporation is pleased to announce a new relationship with Hampshire and Isle of Wight (HIOW) health and care system to enable their population health management journey to transform the...